Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling ; volume:18 ; number:1 ; day:1 ; month:3 ; year:2016 ; pages:1-9 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (1.3.2016), 1-9, 12.2016
- Creator
-
Boyer, Jean Frédéric
- Contributor
-
Baron, Michel
Constantin, Arnaud
Degboé, Yannick
Cantagrel, Alain
Davignon, Jean-Luc
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-0955-8
- URN
-
urn:nbn:de:1111-2016073038954
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:48:32+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Boyer, Jean Frédéric
- Baron, Michel
- Constantin, Arnaud
- Degboé, Yannick
- Cantagrel, Alain
- Davignon, Jean-Luc
- SpringerLink (Online service)
Other Objects (12)
Monitoring of anti-TNF biological treatments
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
The effects of anti–TNF agents on the expansion of T helper-type 17 cells driven by lipopolysaccharide-stimulated monocytes
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
A review of ocular adverse events of biological anti-TNF drugs
Monitoring of anti-TNF biological treatments
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
The effects of anti–TNF agents on the expansion of T helper-type 17 cells driven by lipopolysaccharide-stimulated monocytes
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen
A review of ocular adverse events of biological anti-TNF drugs
Monitoring of anti-TNF biological treatments
Stopping Anti-TNF in CD Remitters: Cons
Development of anti-TNF antibody-gold nanoparticles (anti-TNF-AuNPs)
Anti-TNF, a magic bullet in cancer immunotherapy?
Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment
Predictors of response and anti-TNF drugs comparative efficacy
Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
The effects of anti–TNF agents on the expansion of T helper-type 17 cells driven by lipopolysaccharide-stimulated monocytes
Predictive biomarkers for anti-TNF alpha therapy in IBD patients
Der molekulare Wirkmechanismus der anti-TNF Antikörper bei chronisch entzündlichen Darmerkrankungen